Sponsored Symposia

Personalising Type 2 asthma treatment with Dupilumab – evidence and clinical experience

Session Date: Saturday, 1 May 2021
Session Time: 0700-0815

Local speaker and an international speaker, both are currently being engaged (TBC)

Following Dupixent asthma recommendation made by PBAC, Sanofi would like to align with requests from HCPs about Dupixent’s clinical evidence and experience gained by HCPs in previously launched international markets as well as from their peers locally. Symposium aims to provide practical guidance on where Dupixent fits into severe asthma management and what factors influence the choice of biologic therapy to achieve best possible outcomes for asthma patients. Dupixent is a human monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines that play a central role in type 2 inflammation that underlies specific types of asthma as well as several other allergic diseases. Dupixent is indicated in Australia for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy, not indicated for episodic use. Dupixent is also indicated for add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO). It is indicated as maintenance therapy for oral corticosteroid dependent asthma.

Advances in Functional Lung Imaging: Translational Medicine and Clinical Applications


Date: Saturday, 1 May
Time: 1320-1350

Professor Naresh M. Punjabi MD, PhD, Chief of Pulmonary Critical Care & Sleep Medicine, University of Miami

Understanding of the determinants of ventilation defects and ventilation heterogeneity may lead to more efficacious treatments for acute and chronic lung diseases, and can provide an additional approach for monitoring treatments to improve long-term outcomes for patients. This symposium addresses state-of-the-art, non-invasive lung imaging used to determine functional deficits in regional lung motion and airflow.

From lab to Lizzy – the Australian story behind eosinophils


Date: Saturday 1 May
Time: 1850-2005 

Dr Li Ping Chung, Fiona Stanley Hospital, Western Australia
Professor Paul Foster, The University of Newcastle, Hunter Medical Research Institute
Professor Peter Gibson, The University of Newcastle, Hunter Medical Research Institute
Professor Vanessa McDonald, The University of Newcastle, Hunter Medical Research Institute

Chair: Dr Li Ping Chung, Fiona Stanley Hospital, Western Australia

We invite you to take a step back in time and trace the journey of the eosinophils and IL-5 from discovery to patient. In this meeting we will hear from Australian investigators and researchers who have led the discovery, development and real world application of targeted therapies such as mepolizumab (Nucala). Lizzy*, a patient from the Australian Mepolizumab Registry will also join us to share her experience of living with severe asthma.

(*Lizzy is a fictional name used for the purposes of the synopsis, we are planning to have a real patient as part of the symposium).

Targeting peripheral airways dysfunction in the management of COPD


Date: Sunday, 2 May
Time: 1320-1350

Prof Bruce Thompson and Dr John Blakey

Chair: Prof Bruce Thompson

Despite the prevalence of COPD being as high as 1 in 7 Australians over the age of 40 years and the second leading cause of preventable hospital admissions in Australia1, the diagnosis and management of this obstructive lung condition remain suboptimal.

COPD is a disease of the peripheral or “small airways” and evidence has shown that small airways inflammation is present even in mild disease. Recent research has seen a resurgence in physiological and imaging techniques that are able to reliably assess and characterise peripheral airways in COPD patients. This has led to an interest in studying the effect of small particle sized inhaled therapies that are able to reach and potentially treat the peripheral airways.

This session will provide an update to participants on the evidence supporting treatment of COPD with a new PBS-listed extrafine fixed combination ICS/LABA/LAMA pMDI and its place in therapy in the Australian context. In addition, this update aims to educate Australian healthcare professionals on key changes to local and international guidelines to guide their management of their COPD patients.

  1. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald V, Smith B, Zwar N, Dabscheck E. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2020. Version 2.61, February 2020.